Cargando…

CSF levels of synaptosomal-associated protein 25 and synaptotagmin-1 in first-episode psychosis subjects

Post-mortem studies consistently show evidence of reduced synaptic protein levels in patients with schizophrenia. Clinically high-risk subjects show a steeper decrease in grey matter thickness and in vitro modeling using patient-derived cells implicate excessive synaptic pruning during neurodevelopm...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Chengai, Sellgren, Carl M., Fatouros-Bergman, Helena, Piehl, Fredrik, Blennow, Kaj, Zetterberg, Henrik, Brinkmalm, Ann, Santillo, Alexander Frizell, Lundgren, Sofia, Cervenka, Simon, Engberg, Göran, Erhardt, Sophie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7262376/
https://www.ncbi.nlm.nih.gov/pubmed/32490278
http://dx.doi.org/10.1016/j.ibror.2020.04.001
_version_ 1783540615910260736
author Xu, Chengai
Sellgren, Carl M.
Fatouros-Bergman, Helena
Piehl, Fredrik
Blennow, Kaj
Zetterberg, Henrik
Brinkmalm, Ann
Santillo, Alexander Frizell
Lundgren, Sofia
Cervenka, Simon
Engberg, Göran
Erhardt, Sophie
author_facet Xu, Chengai
Sellgren, Carl M.
Fatouros-Bergman, Helena
Piehl, Fredrik
Blennow, Kaj
Zetterberg, Henrik
Brinkmalm, Ann
Santillo, Alexander Frizell
Lundgren, Sofia
Cervenka, Simon
Engberg, Göran
Erhardt, Sophie
author_sort Xu, Chengai
collection PubMed
description Post-mortem studies consistently show evidence of reduced synaptic protein levels in patients with schizophrenia. Clinically high-risk subjects show a steeper decrease in grey matter thickness and in vitro modeling using patient-derived cells implicate excessive synaptic pruning during neurodevelopment as a part of the schizophrenia pathophysiology. However, it is unclear to what extent synapse elimination is present during various stages of the disease, which is of clinical importance as in a real-world setting most subjects received their first-episode psychosis (FEP) diagnosis not until their mid-twenties. In the present study, we measured cerebrospinal fluid (CSF) concentrations of the two pre-synaptic proteins synaptosomal-associated protein 25 (SNAP-25) and synaptotagmin-1 (SYT-1), both of which are increased in conditions of ongoing synaptic degeneration, in 44 FEP subjects (mean age 29.9 years) and 21 healthy controls (25.9 years) using immunoprecipitation mass spectrometry. Neither protein was found to differ between healthy controls and patients, and they showed no correlation with symptom ratings, cognitive performance or antipsychotic medication. Additional studies in high-risk subjects in the early prodromal phase will be needed to address if excessive synapse destruction occurs before the development of overt psychotic symptoms.
format Online
Article
Text
id pubmed-7262376
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-72623762020-06-01 CSF levels of synaptosomal-associated protein 25 and synaptotagmin-1 in first-episode psychosis subjects Xu, Chengai Sellgren, Carl M. Fatouros-Bergman, Helena Piehl, Fredrik Blennow, Kaj Zetterberg, Henrik Brinkmalm, Ann Santillo, Alexander Frizell Lundgren, Sofia Cervenka, Simon Engberg, Göran Erhardt, Sophie IBRO Rep Article Post-mortem studies consistently show evidence of reduced synaptic protein levels in patients with schizophrenia. Clinically high-risk subjects show a steeper decrease in grey matter thickness and in vitro modeling using patient-derived cells implicate excessive synaptic pruning during neurodevelopment as a part of the schizophrenia pathophysiology. However, it is unclear to what extent synapse elimination is present during various stages of the disease, which is of clinical importance as in a real-world setting most subjects received their first-episode psychosis (FEP) diagnosis not until their mid-twenties. In the present study, we measured cerebrospinal fluid (CSF) concentrations of the two pre-synaptic proteins synaptosomal-associated protein 25 (SNAP-25) and synaptotagmin-1 (SYT-1), both of which are increased in conditions of ongoing synaptic degeneration, in 44 FEP subjects (mean age 29.9 years) and 21 healthy controls (25.9 years) using immunoprecipitation mass spectrometry. Neither protein was found to differ between healthy controls and patients, and they showed no correlation with symptom ratings, cognitive performance or antipsychotic medication. Additional studies in high-risk subjects in the early prodromal phase will be needed to address if excessive synapse destruction occurs before the development of overt psychotic symptoms. Elsevier 2020-04-13 /pmc/articles/PMC7262376/ /pubmed/32490278 http://dx.doi.org/10.1016/j.ibror.2020.04.001 Text en © 2020 The Author(s) http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Article
Xu, Chengai
Sellgren, Carl M.
Fatouros-Bergman, Helena
Piehl, Fredrik
Blennow, Kaj
Zetterberg, Henrik
Brinkmalm, Ann
Santillo, Alexander Frizell
Lundgren, Sofia
Cervenka, Simon
Engberg, Göran
Erhardt, Sophie
CSF levels of synaptosomal-associated protein 25 and synaptotagmin-1 in first-episode psychosis subjects
title CSF levels of synaptosomal-associated protein 25 and synaptotagmin-1 in first-episode psychosis subjects
title_full CSF levels of synaptosomal-associated protein 25 and synaptotagmin-1 in first-episode psychosis subjects
title_fullStr CSF levels of synaptosomal-associated protein 25 and synaptotagmin-1 in first-episode psychosis subjects
title_full_unstemmed CSF levels of synaptosomal-associated protein 25 and synaptotagmin-1 in first-episode psychosis subjects
title_short CSF levels of synaptosomal-associated protein 25 and synaptotagmin-1 in first-episode psychosis subjects
title_sort csf levels of synaptosomal-associated protein 25 and synaptotagmin-1 in first-episode psychosis subjects
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7262376/
https://www.ncbi.nlm.nih.gov/pubmed/32490278
http://dx.doi.org/10.1016/j.ibror.2020.04.001
work_keys_str_mv AT xuchengai csflevelsofsynaptosomalassociatedprotein25andsynaptotagmin1infirstepisodepsychosissubjects
AT sellgrencarlm csflevelsofsynaptosomalassociatedprotein25andsynaptotagmin1infirstepisodepsychosissubjects
AT fatourosbergmanhelena csflevelsofsynaptosomalassociatedprotein25andsynaptotagmin1infirstepisodepsychosissubjects
AT piehlfredrik csflevelsofsynaptosomalassociatedprotein25andsynaptotagmin1infirstepisodepsychosissubjects
AT blennowkaj csflevelsofsynaptosomalassociatedprotein25andsynaptotagmin1infirstepisodepsychosissubjects
AT zetterberghenrik csflevelsofsynaptosomalassociatedprotein25andsynaptotagmin1infirstepisodepsychosissubjects
AT brinkmalmann csflevelsofsynaptosomalassociatedprotein25andsynaptotagmin1infirstepisodepsychosissubjects
AT santilloalexanderfrizell csflevelsofsynaptosomalassociatedprotein25andsynaptotagmin1infirstepisodepsychosissubjects
AT lundgrensofia csflevelsofsynaptosomalassociatedprotein25andsynaptotagmin1infirstepisodepsychosissubjects
AT cervenkasimon csflevelsofsynaptosomalassociatedprotein25andsynaptotagmin1infirstepisodepsychosissubjects
AT engberggoran csflevelsofsynaptosomalassociatedprotein25andsynaptotagmin1infirstepisodepsychosissubjects
AT erhardtsophie csflevelsofsynaptosomalassociatedprotein25andsynaptotagmin1infirstepisodepsychosissubjects
AT csflevelsofsynaptosomalassociatedprotein25andsynaptotagmin1infirstepisodepsychosissubjects